GLENMARK PHARMACEUTICALS
Back to Income Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Revenue History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Net Sales | ₹11,583 Cr | ₹12,305 Cr | ₹10,944 Cr | ₹10,641 Cr | ₹9,865 Cr |
What is the latest Revenue of GLENMARK PHARMACEUTICALS ?
Year | Revenue |
---|---|
Mar2024 | ₹11,583 Cr |
Mar2023 | ₹12,305 Cr |
Mar2022 | ₹10,944 Cr |
Mar2021 | ₹10,641 Cr |
Mar2020 | ₹9,865 Cr |
How is Revenue of GLENMARK PHARMACEUTICALS Trending?
Years | Revenue | % Change | |
---|---|---|---|
Mar2024 | ₹11,583 Cr | -5.86 | |
Mar2023 | ₹12,305 Cr | 12.44 | |
Mar2022 | ₹10,944 Cr | 2.85 | |
Mar2021 | ₹10,641 Cr | 7.86 | |
Mar2020 | ₹9,865 Cr | - |
Compare Revenue of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹40,810.4 Cr | 3.7% | 5% | 40.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹417,400.0 Cr | -0.3% | 3.1% | 13.4% | Stock Analytics | |
DIVIS LABORATORIES | ₹164,844.0 Cr | 3.5% | 11% | 63.5% | Stock Analytics | |
CIPLA | ₹121,328.0 Cr | 1.6% | 2.7% | 11.6% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹110,521.0 Cr | 4.1% | 4.4% | 24.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,043.0 Cr | 6.8% | 11.3% | 3.1% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 3.7% |
5% |
40.9% |
SENSEX | 2.7% |
11.8% |
14% |
You may also like the below Video Courses